Back to BIIB Stock Lookup

BIIB Related Analyst Comments

May 20, 2013 04:43 PM Biogen's (BIIB) BG-12 Data Not Inflated

May 20, 2013 10:06 AM Biogen (BIIB) Weeks-6 TECFIDERA Scripts Continue to Ramp

May 13, 2013 09:41 AM Biogen's (BIIB) TECFIDERA Scripts Accelerating WoW

May 6, 2013 08:40 AM Scripts Data Indicates Biogen's (BIIB) Tecfidera Could Beat 2013 Estimates by $400M

May 1, 2013 06:45 AM Goldman Sachs Upgrades Amgen (AMGN) to Conviction Buy

Apr 29, 2013 12:53 PM Deutsche Bank Sees Upside for Biogen's (BIIB) Tecfidera

Apr 26, 2013 08:03 AM Jefferies Lifts Numbers on Biogen (BIIB) Post Q1

Apr 25, 2013 02:00 PM Deutsche Bank Maintains Buy on Biogen (BIIB)

Apr 22, 2013 05:24 PM Deutsche Bank Raises Biogen (BIIB) Price Target to $240

Apr 22, 2013 12:59 PM Strong Biogen (BIIB) Tecfideara Sales Tied to Patient 'Warehousing'

Apr 22, 2013 08:48 AM Early Data Says Biogen's (BIIB) Tecfidera Doing Well - Analyst

Mar 28, 2013 09:12 AM Biogen (BIIB) Target Raised to $215 at Jefferies after Tecfidera Approved with Favorable Label

Mar 27, 2013 05:43 PM What Next for Biogen (BIIB)? Anlaysts Weigh In

Mar 25, 2013 08:40 AM Jefferies Maintains Bullish Stance on Biogen (BIIB) after AAN Meeting

Feb 6, 2013 03:50 PM Deutsche Bank Boosts PT on Biogen (BIIB) to $170 on Tysabri Deal

Nov 21, 2012 10:27 AM Notable Analyst Rating Changes 11/21: (PENN) (THOR) (SKX) Upgraded; (HTWR) (EV) (ICA) Downgraded

Sep 27, 2012 07:37 AM Jefferies Lifts Target on Biogen (BIIB) to $176, Hemophilia Data Adds To Valuation

Sep 26, 2012 11:36 AM Baxter (BAX) Smacked on Solid Results from Biogen's (BIIB) Hemophilia Drug

Sep 11, 2012 08:57 AM Cantor Fitzgerald Reiterates a 'Buy' on Sunesis Pharmaceuticals (SNSS); Market Potential for Vosaroxin

Sep 10, 2012 12:55 PM UBS on U.S. Biotechnology - Updating Outlook on Covered Stocks (GILD, AMGN, BIIB, CELG, INCY, IDIX, VRTX, SGEN)

Jul 25, 2012 01:29 PM UBS Maintains a 'Buy' on Biogen (BIIB); Key Takeaways from 2Q12

Jul 25, 2012 10:05 AM Jefferies Maintains a 'Buy' on Biogen (BIIB) on Strong Q2; Adjusting Numbers

Jul 6, 2012 02:01 PM Q2 Kickoff: Alcoa (AA) Investors to Focus on LME Prices, Downstream Ops, and China

Jul 5, 2012 10:47 AM Wells Fargo on Biogen (BIIB): Price Increases in MS Space Should Offer More Flexibility for BG-12

Jul 5, 2012 09:58 AM Elan Corp (ELN) Has Mutlipe Items Driving Action Today

May 11, 2012 01:26 PM Barclays on Healthcare: Top Takeaways from our Second Annual Therapeutics Symposium

May 10, 2012 12:26 PM Goldman Sachs Said Biogen's (BIIB) BG-12 Acceptance Should Alliaate Concerns

May 9, 2012 12:38 PM UBS Maintains a 'Buy' on Biogen (BIIB); Core Franchise Support Valuation; Pipeline Provides Upside Risk

May 2, 2012 02:47 PM Jefferies Increases Price Target in Biogen (BIIB)

May 2, 2012 07:55 AM Goldman Sachs Maintains Bullish Stance on Biogen (BIIB), Sees Room for Significant Upside

May 1, 2012 03:58 PM Baird Maintains a 'Neutral' on Biogen (BIIB); Still Prefer the Sidelines as Pipeline Remains The Focus

Apr 30, 2012 07:13 AM Deutsche Bank maintains a 'Buy' on Biogen Idec (BIIB); Hemophilia Survey Suggests Market Share Gains

Apr 23, 2012 08:06 AM Jefferies Maintains a 'Buy' on Biogen (BIIB); Favorable Gilenya Update

Apr 19, 2012 10:38 AM Baird Maintains a 'Neutral' on Biogen (NASDAQ: BIIB); Raising Estimates Ahead of Earnings

Mar 15, 2012 08:25 AM Jefferies Maintains Bullish View on Biogen (BIIB) After Positive Hemophilia Pipeline Feedback

Jan 31, 2012 04:07 PM Baird Reiterates a 'Neutral' on Biogen (BIIB); Conservative FY12 Guidance - However Still All About Pipeline

Jan 30, 2012 03:35 PM Cramer Pounds the Table on Biogen Idec (BIIB) Ahead of BG-12 Filing

Dec 9, 2011 01:15 PM Barclays Initiating Coverage: A Seamless Approach to Biopharmaceuticals

Oct 31, 2011 11:43 AM UBS Maintains a 'Buy' on Biogen (BIIB); Raising PT on MS Franchise Strength

Oct 27, 2011 07:32 AM Jefferies Lifts Price Target on Biogen (BIIB), Strong CONFIRM Data Bodes Well For BG-12 Positioning

Oct 26, 2011 01:31 PM Baird Maintains a 'Neutral' on Biogen (BIIB); CONFIRM Hits; BG12 Approvable; Commercial Uptake the Next Question

Oct 21, 2011 12:25 PM Jefferies Comments on Biogen (BIIB) Following Further BG12 Phase 3 DEFINE Analysis; Remains Bullish on Prospects in MS Use

Oct 5, 2011 09:44 AM Jefferies Comments on Biogen (BIIB), Sees Buying Opportunity

Sep 19, 2011 01:10 PM Jefferies Comments on Elan Corp (ELN), Making Moves in The Right Direction

Sep 13, 2011 08:43 AM Baird Maintains a 'Neutral' on Biogen (BIIB); Hemophilia Update Moderately Incremental; Still All About BG-12

Aug 9, 2011 01:16 PM Citadel Securities Maintains an 'Add' Biogen Idec (BIIB); Daclizumab May Add Leverage to Growing MS Franchise

Aug 2, 2011 09:27 AM Jefferies Sees Failure of Phase 3 BRAVO Study as a Positive for Biogen (BIIB)

Aug 1, 2011 02:57 PM Baird Maintains Acorda Therapeutics (ACOR) Neutral Rating, Says Takeout Still Seems Best Option

Jul 27, 2011 10:43 AM UBS Maintains a 'Neutral' on Biogen (BIIB); Updating Model for 2Q

Jul 27, 2011 09:01 AM Jefferies Raises Price Target & Estimates on Biogen (BIIB), Strong Tysabri Sales

Back to BIIB Stock Lookup